Skip to main content
Top
Published in: Abdominal Radiology 2/2020

01-02-2020 | Magnetic Resonance Imaging | Review

MRI of the liver: choosing the right contrast agent

Authors: Christopher L. Welle, Flavius F. Guglielmo, Sudhakar K. Venkatesh

Published in: Abdominal Radiology | Issue 2/2020

Login to get access

Abstract

Contrast enhanced MRI of the liver provides valuable information in the evaluation of both chronic liver disease and focal liver lesions. Currently, two classes of MRI contrast agents are available for clinical use, namely the extracellular contrast agent (ECA) and the hepatobiliary agent (HBA). The use of appropriate contrast agents for liver MRI requires knowledge of the clinical situation and question to be answered. ECAs have been used for decades since their introduction into clinical practice and provide excellent dynamic phase information that is useful in characterizing focal liver lesions. In the last decade, HBAs, particularly Gadoxetate, have been found useful for characterizing lesions with functioning hepatocytes and more importantly in evaluating the biliary tree. Gadoxetate, however, provides less satisfactory dynamic phase images compared to ECAs, particularly during the arterial phase. In this perspective article, we will discuss the various intravenous contrast agents used for liver MRI and their ideal utilization.
Literature
1.
go back to reference Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB (2006) MR contrast agents for liver imaging: what, when, how. Radiographics 26 (6):1621-1636.CrossRefPubMed Gandhi SN, Brown MA, Wong JG, Aguirre DA, Sirlin CB (2006) MR contrast agents for liver imaging: what, when, how. Radiographics 26 (6):1621-1636.CrossRefPubMed
6.
go back to reference Hadizadeh DR, Gieseke J, Lohmaier SH, Wilhelm K, Boschewitz J, Verrel F, Schild HH, Willinek WA (2008) Peripheral MR angiography with blood pool contrast agent: prospective intraindividual comparative study of high-spatial-resolution steady-state MR angiography versus standard-resolution first-pass MR angiography and DSA. Radiology 249 (2):701-711. https://doi.org/10.1148/radiol.2492072033 CrossRefPubMed Hadizadeh DR, Gieseke J, Lohmaier SH, Wilhelm K, Boschewitz J, Verrel F, Schild HH, Willinek WA (2008) Peripheral MR angiography with blood pool contrast agent: prospective intraindividual comparative study of high-spatial-resolution steady-state MR angiography versus standard-resolution first-pass MR angiography and DSA. Radiology 249 (2):701-711. https://​doi.​org/​10.​1148/​radiol.​2492072033 CrossRefPubMed
14.
go back to reference Kitao A, Matsui O, Yoneda N, Kita R, Kozaka K, Kobayashi S, Gabata T (2018) Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI. AJR Am J Roentgenol 211 (2):347-357. https://doi.org/10.2214/ajr.17.19341 CrossRefPubMed Kitao A, Matsui O, Yoneda N, Kita R, Kozaka K, Kobayashi S, Gabata T (2018) Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI. AJR Am J Roentgenol 211 (2):347-357. https://​doi.​org/​10.​2214/​ajr.​17.​19341 CrossRefPubMed
16.
18.
go back to reference Bieze M, van den Esschert JW, Nio CY, Verheij J, Reitsma JB, Terpstra V, van Gulik TM, Phoa SS (2012) Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol 199 (1):26-34. https://doi.org/10.2214/ajr.11.7750 CrossRefPubMed Bieze M, van den Esschert JW, Nio CY, Verheij J, Reitsma JB, Terpstra V, van Gulik TM, Phoa SS (2012) Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. AJR Am J Roentgenol 199 (1):26-34. https://​doi.​org/​10.​2214/​ajr.​11.​7750 CrossRefPubMed
23.
go back to reference Elsayes KM, Kielar AZ, Elmohr MM, Chernyak V, Masch WR, Furlan A, Marks RM, Cruite I, Fowler KJ, Tang A, Bashir MR, Hecht EM, Kamaya A, Jambhekar K, Kamath A, Arora S, Bijan B, Ash R, Kassam Z, Chaudhry H, McGahan JP, Yacoub JH, McInnes M, Fung AW, Shanbhogue K, Lee J, Deshmukh S, Horvat N, Mitchell DG, Do RKG, Surabhi VR, Szklaruk J, Sirlin CB (2018) White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI. Abdom Radiol (NY) 43 (10):2625-2642. https://doi.org/10.1007/s00261-018-1744-4 CrossRef Elsayes KM, Kielar AZ, Elmohr MM, Chernyak V, Masch WR, Furlan A, Marks RM, Cruite I, Fowler KJ, Tang A, Bashir MR, Hecht EM, Kamaya A, Jambhekar K, Kamath A, Arora S, Bijan B, Ash R, Kassam Z, Chaudhry H, McGahan JP, Yacoub JH, McInnes M, Fung AW, Shanbhogue K, Lee J, Deshmukh S, Horvat N, Mitchell DG, Do RKG, Surabhi VR, Szklaruk J, Sirlin CB (2018) White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI. Abdom Radiol (NY) 43 (10):2625-2642. https://​doi.​org/​10.​1007/​s00261-018-1744-4 CrossRef
24.
go back to reference Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, Knight-Greenfield A, Babb JS, Boffetta P, Padron N, Sirlin CB, Taouli B (2017) Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY) 42 (1):179-190. https://doi.org/10.1007/s00261-016-0841-5 CrossRef Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, Knight-Greenfield A, Babb JS, Boffetta P, Padron N, Sirlin CB, Taouli B (2017) Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY) 42 (1):179-190. https://​doi.​org/​10.​1007/​s00261-016-0841-5 CrossRef
Metadata
Title
MRI of the liver: choosing the right contrast agent
Authors
Christopher L. Welle
Flavius F. Guglielmo
Sudhakar K. Venkatesh
Publication date
01-02-2020
Publisher
Springer US
Published in
Abdominal Radiology / Issue 2/2020
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-019-02162-5

Other articles of this Issue 2/2020

Abdominal Radiology 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.